Fig 1.
Threshold determination of IMC-βγ.
A. IMC-βγ values in neurotypical subjects (n = 83) and ALS patients (n = 123). The dashed line is the cutoff threshold of 0.025, below which IMC-βγ is considered abnormal. B. Accuracy, sensitivity and specificity of IMC-βγ in distinguishing neurotypical from ALS patients, as a function of the IMC value used as a cutoff for abnormal. Dashed line shows the cutoff displayed in A. C. ROC curve showing sensitivity and 1-specificity of the IMC test as a function IMC cutoff value. Area under the curve 0.78.
Fig 2.
Two provisional diagnoses will be made at initial presentation: one based on the Awaji criteria alone, and one based on the Awaji criteria with IMC assessment. Every 6 months a patient’s clinical record will be reviewed to assign a final diagnosis. After a final diagnosis is determined, the performance at initial presentation of the Awaji+IMC criteria will be compared to that of Awaji alone.
Fig 3.
Cross-classification of initial Awaji with Awaji+IMC results by final diagnosis.
A = Awaji criteria at initial visit, A+I = Awaji+IMC criteria at initial visit, +: definite or probable category, -: possible or uncategorized.